Open Orphan plc (LON:ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals..
Open Orphan plc (LON:ORPH) Chief Executive Officer Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss that hVIVO has begun testing of an antiviral for COVID-19. Q1:..
Open Orphan plc (LON:ORPH) CEO Cathal Friel joins DirectorsTalk to discuss the testing of an anti-viral for treating COVID-19. Cathal explains whats involved in the testing, the time frames involved..
Open Orphan plc (LON:ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and..
Open Orphan plc (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and..
Open Orphan PLC (LON:ORPH) Chief Executive Officer Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss the world’s first human coronavirus challenge study model. Q1: We’ve just..
Open Orphan PLC (LON:ORPH) Chief Executive Officer Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss the new hVIVO contract signed with a European biotech company. Q1:..
Open Orphan plc (LON:ORPH) in a string of positive news releases catch up with DirectorsTalk to discuss two human study challenges. Executive Chairman Cathal Friel joins DirectorsTalk to discuss the..
Positive results from Phase IIb field study of FLU-v vaccine (FLU-v 003), which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group. FLU-v is a..
Open Orphan plc (LON:ORPH), the rapidly growing specialist Clinical Research Organisation pharmaceutical services company whose London-based subsidiary hVIVO is the world leader in the provision of virology and vaccine challenge..
Respiratory Syncytial Virus human challenge study Projected to deliver £3.2m in revenue in 2020 with the pivotal challenge study expected to commence end Q4 2020, with the potential to deliver..
Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and..
Open Orphan plc (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and..
Open Orphan plc (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and..
Open Orphan plc (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and..
Open Orphan plc (LON:ORPH) Co-Founder and Executive Chairman Cathal Friel talks us though the Feb 2020 Investor Presentation. Open Orphan was founded in 2017, with the goal of rapidly building..
Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and..
